GGrantIndex
← Search

Genomics Shared Resource

$232,267P30FY2023CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward GENOMICS SHARED RESOURCE - PROJECT SUMMARY/ABSTRACT The Genomics Shared Resource (GSR) integrates our legacy Genomics, Epigenomics, Computational Genomics and Molecular Cytogenetics core facilities. As a result of this integration, we have combined the activities and expertise of individuals in core facilities performing closely related work into a unified entity that enhances efficiency and quality of services so that cancer researchers can hand off samples to core personnel and receive analyzed data, providing a complete workflow housed in a single facility. The GSR is now implementing long-read sequencing services in addition to short-read services. When appropriate, we facilitate outsourcing of short-read sequencing to low-cost commercial providers. However, we have recently purchased the Illumina NextSeq 2000 platform that upgrades our short read sequencing capabilities. This investment anticipates a substantial drop in reagent costs in the next 1-2 years and migration of some of the currently outsourced sequencing back into the GSR. The GSR has also been proactive in optimizing new single cell assays for researchers with a current focus on single cell RNA-sequencing and chromatin assays as well as spatial transcriptomics of tissue sections. Cost savings through multiplexing for single cell experiments on the 10X Chromium platform has been used to make these assays substantially more cost-efficient, while reducing batch effects. Single cell sequencing combined with cell surface marker studies are being provided using the Mission Bio Tapestri platform, which is a foundation for ongoing clonal hematopoiesis research. We have increased our focus on collecting genomics data as a resource within the GSR. Our new institutional arrangement with Caris Life Sciences to perform exome and transcriptome sequencing on our Bronx cancer patients is accompanied by a research protocol to allow the primary sequence data to be returned to our FISMA-compliant data storage and computing resource. These data are made available under defined IRB protocols for researchers, to gain insights into the genomic events occurring in the ancestrally diverse, socioeconomically disadvantaged communities of the Bronx. Our goals for the next funding period will be to continue to support MECC researchers in their genomic assays and data analyses. We are continuing to develop and support new assays, to invest in new equipment, and to help analyze data generated in the GSR. Investigators are encouraged to contact the leaders of the GSR and Biostatistics colleagues to discuss study design before initiating a project. For data analytical services, we will continue to train lab personnel to process data independently and can troubleshoot problems with researchers. Finally, a new goal is to tailor our services so that they allow insights into cancer genomics in the ancestrally- diverse Bronx population, with the goal that GSR can help foster health equity and precision medicine for all. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page

View original record on NIH RePORTER →